Peter P. De Deyn - Publications

Affiliations: 
Universiteit Antwerpen (Belgium) 
Area:
Toxicology, Neuroscience Biology

118 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Frentz I, van Arendonk J, Leeuwis AE, Vernooij MW, van der Flier WM, Bos D, De Deyn PP, Wolters FJ, Ikram MA. Interaction Between Arteriosclerosis and Amyloid-β on Cognitive Function. Journal of Alzheimer's Disease : Jad. 97: 953-961. PMID 38217596 DOI: 10.3233/JAD-230604  0.359
2023 Zhang T, Musheshe N, van der Veen CHJTM, Kessels HW, Dolga A, De Deyn P, Eisel U, Schmidt M. The Expression of Epac2 and GluA3 in an Alzheimer's Disease Experimental Model and Postmortem Patient Samples. Biomedicines. 11. PMID 37626593 DOI: 10.3390/biomedicines11082096  0.358
2023 Heylen A, Vermeiren Y, Kema IP, van Faassen M, van der Ley C, Van Dam D, De Deyn PP. Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD. Pharmaceuticals (Basel, Switzerland). 16. PMID 37111372 DOI: 10.3390/ph16040615  0.31
2022 Laton J, Van Schependom J, Goossens J, Wiels W, Sieben A, De Deyn PP, Goeman J, Streffer J, van der Zee J, Martin JJ, Van Broeckhoven C, De Vos M, Bjerke M, Nagels G, Engelborghs S. Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study. Journal of Alzheimer's Disease : Jad. 90: 1739-1747. PMID 36336933 DOI: 10.3233/JAD-220693  0.361
2022 Gossye H, Van Mossevelde S, Sieben A, Bjerke M, Van de Craen EH, van der Zee J, De Deyn PP, De Bleecker J, Versijpt J, van den Ende J, Deryck O, Bourgeois P, Bier JC, Goethals M, Vandenberghe R, et al. Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum. Brain : a Journal of Neurology. PMID 36171642 DOI: 10.1093/brain/awac362  0.385
2022 Jansen IE, van der Lee SJ, Gomez-Fonseca D, de Rojas I, Dalmasso MC, Grenier-Boley B, Zettergren A, Mishra A, Ali M, Andrade V, Bellenguez C, Kleineidam L, Küçükali F, Sung YJ, Tesí N, ... ... de Deyn PP, et al. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. Acta Neuropathologica. PMID 36066633 DOI: 10.1007/s00401-022-02454-z  0.389
2022 Ortí-Casañ N, Zuhorn IS, Naudé PJW, De Deyn PP, van Schaik PEM, Wajant H, Eisel ULM. A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer's disease mouse model. Proceedings of the National Academy of Sciences of the United States of America. 119: e2201137119. PMID 36037389 DOI: 10.1073/pnas.2201137119  0.321
2022 Peretti DE, Vállez García D, Renken RJ, Reesink FE, Doorduin J, de Jong BM, De Deyn PP, Dierckx RAJO, Boellaard R. Alzheimer's disease pattern derived from relative cerebral flow as an alternative for the metabolic pattern using SSM/PCA. Ejnmmi Research. 12: 37. PMID 35737201 DOI: 10.1186/s13550-022-00909-8  0.302
2022 Marcolini S, Frentz I, Catasus CAS, Mondragon JD, Feltes PK, van der Hoorn A, Borra RJH, Ikram MA, Dierckx RAJO, De Deyn PP. Effects of Interventions on Cerebral Perfusion in the Alzheimer's Disease Spectrum: A Systematic Review. Ageing Research Reviews. 101661. PMID 35671869 DOI: 10.1016/j.arr.2022.101661  0.346
2022 de Rijke TJ, Doting MHE, van Hemert S, De Deyn PP, van Munster BC, Harmsen HJM, Sommer IEC. A Systematic Review on the Effects of Different Types of Probiotics in Animal Alzheimer's Disease Studies. Frontiers in Psychiatry. 13: 879491. PMID 35573324 DOI: 10.3389/fpsyt.2022.879491  0.31
2022 Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, Naj AC, Campos-Martin R, Grenier-Boley B, Andrade V, Holmans PA, Boland A, Damotte V, van der Lee SJ, Costa MR, ... ... de Deyn PP, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics. PMID 35379992 DOI: 10.1038/s41588-022-01024-z  0.352
2022 Bridel C, Somers C, Sieben A, Rozemuller A, Niemantsverdriet E, Struyfs H, Vermeiren Y, Van Broeckhoven C, De Deyn PP, Bjerke M, Nagels G, Teunissen CE, Engelborghs S. Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers. Brain : a Journal of Neurology. PMID 35026840 DOI: 10.1093/brain/awac013  0.363
2021 Mondragón JD, Marapin R, De Deyn PP, Maurits N. Short- and Long-Term Functional Connectivity Differences Associated with Alzheimer's Disease Progression. Dementia and Geriatric Cognitive Disorders Extra. 11: 235-249. PMID 34721501 DOI: 10.1159/000518233  0.306
2021 Solas M, Van Dam D, Janssens J, Ocariz U, Vermeiren Y, De Deyn PP, Ramirez MJ. 5-HT receptors in Alzheimer's disease. Neurochemistry International. 150: 105185. PMID 34555475 DOI: 10.1016/j.neuint.2021.105185  0.302
2021 Willemse EAJ, Sieben A, Somers C, Vermeiren Y, De Roeck N, Timmers M, Van Broeckhoven C, De Vil B, Cras P, De Deyn PP, Martin JJ, Teunissen CE, Engelborghs S, Bjerke M. Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. Neurobiology of Aging. 108: 99-109. PMID 34551375 DOI: 10.1016/j.neurobiolaging.2021.08.002  0.37
2021 Nous A, Wittens MMJ, Vermeiren Y, De Deyn PP, Van Broeckhoven C, Nagels G, Smolders I, Engelborghs S. Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer's Disease but Are Not Correlated with Cognitive Decline. Journal of Alzheimer's Disease : Jad. PMID 34366353 DOI: 10.3233/JAD-210562  0.34
2021 Naudé PJW, Ramakers IHGB, van der Flier WM, Jiskoot LC, Reesink FE, Claassen JAHR, Koek HL, Eisel ULM, De Deyn PP. Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. Neurobiology of Aging. 107: 1-10. PMID 34365256 DOI: 10.1016/j.neurobiolaging.2021.07.001  0.4
2021 Wittens MMJ, Sima DM, Houbrechts R, Ribbens A, Niemantsverdriet E, Fransen E, Bastin C, Benoit F, Bergmans B, Bier JC, De Deyn PP, Deryck O, Hanseeuw B, Ivanoiu A, Lemper JC, et al. Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. Journal of Alzheimer's Disease : Jad. PMID 34334402 DOI: 10.3233/JAD-210450  0.328
2021 Bron EE, Klein S, Papma JM, Jiskoot LC, Venkatraghavan V, Linders J, Aalten P, De Deyn PP, Biessels GJ, Claassen JAHR, Middelkoop HAM, Smits M, Niessen WJ, van Swieten JC, van der Flier WM, et al. Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. Neuroimage. Clinical. 31: 102712. PMID 34118592 DOI: 10.1016/j.nicl.2021.102712  0.313
2021 Dekker AD, Ulgiati AM, Groen H, Boxelaar VA, Sacco S, Falquero S, Carfi A, di Paola A, Benejam B, Valldeneu S, Fopma R, Oosterik M, Hermelink M, Beugelsdijk G, Schippers M, ... ... De Deyn PP, et al. The Behavioral and Psychological Symptoms of Dementia in Down Syndrome scale (BPSD-DS II): Optimization and Further Validation. Journal of Alzheimer's Disease : Jad. PMID 33967040 DOI: 10.3233/JAD-201427  0.317
2021 Sieben A, Van Langenhove T, Vermeiren Y, Gossye H, Praet M, Vanhauwaert D, Cousaert C, Engelborghs S, Raedt R, Boon P, Santens P, De Deyn PP, Bracke KR, De Meulemeester K, Van Broeckhoven C, et al. Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. Journal of Neuropathology and Experimental Neurology. PMID 33638350 DOI: 10.1093/jnen/nlab010  0.304
2021 Gerrits E, Brouwer N, Kooistra SM, Woodbury ME, Vermeiren Y, Lambourne M, Mulder J, Kummer M, Möller T, Biber K, Dunnen WFAD, De Deyn PP, Eggen BJL, Boddeke EWGM. Distinct amyloid-β and tau-associated microglia profiles in Alzheimer's disease. Acta Neuropathologica. PMID 33609158 DOI: 10.1007/s00401-021-02263-w  0.329
2021 Mondragón JD, Maurits NM, De Deyn PP. Functional connectivity differences in Alzheimer's disease and amnestic mild cognitive impairment associated with AT(N) classification and anosognosia. Neurobiology of Aging. 101: 22-39. PMID 33561787 DOI: 10.1016/j.neurobiolaging.2020.12.021  0.317
2020 Mormont E, Bier JC, Bruffaerts R, Cras P, De Deyn P, Deryck O, Engelborghs S, Petrovic M, Picard G, Segers K, Thiery E, Versijpt J, Hanseeuw B. Practices and opinions about disclosure of the diagnosis of Alzheimer's disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia. Acta Neurologica Belgica. PMID 32715405 DOI: 10.1007/S13760-020-01448-6  0.408
2020 Tumati S, Marsman JC, De Deyn PP, Martens S, Aleman A. Functional network topology associated with apathy in Alzheimer's disease. Journal of Affective Disorders. 266: 473-481. PMID 32056915 DOI: 10.1016/J.Jad.2020.01.158  0.31
2019 Ortí-Casañ N, Wu Y, Naudé PJW, De Deyn PP, Zuhorn IS, Eisel ULM. Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer's Disease. Frontiers in Neuroscience. 13: 49. PMID 30778285 DOI: 10.3389/fnins.2019.00049  0.305
2018 Dekens DW, Naudé PJW, Keijser JN, Boerema AS, De Deyn PP, Eisel ULM. Lipocalin 2 contributes to brain iron dysregulation but does not affect cognition, plaque load, and glial activation in the J20 Alzheimer mouse model. Journal of Neuroinflammation. 15: 330. PMID 30501637 DOI: 10.1186/s12974-018-1372-5  0.308
2018 Perrone F, Cacace R, Van Mossevelde S, Van den Bossche T, De Deyn PP, Cras P, Engelborghs S, van der Zee J, Van Broeckhoven C. Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis. Neurobiology of Aging. PMID 29859640 DOI: 10.1016/J.Neurobiolaging.2018.04.015  0.304
2018 Dekker AD, Vermeiren Y, Carmona-Iragui M, Benejam B, Videla L, Gelpi E, Aerts T, Van Dam D, Fernández S, Lleó A, Videla S, Sieben A, Martin JJ, Blesa R, ... ... De Deyn PP, et al. Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 99-111. PMID 29780859 DOI: 10.1016/j.dadm.2017.11.001  0.352
2018 Dekker AD, Sacco S, Carfi A, Benejam B, Vermeiren Y, Beugelsdijk G, Schippers M, Hassefras L, Eleveld J, Grefelman S, Fopma R, Bomer-Veenboer M, Boti M, Oosterling GDE, Scholten E, ... ... De Deyn PP, et al. The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. Journal of Alzheimer's Disease : Jad. PMID 29689719 DOI: 10.3233/JAD-170920  0.315
2018 Niemantsverdriet E, Feyen BFE, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, Bjerke M, Engelborghs S. Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. Journal of Alzheimer's Disease : Jad. PMID 29614653 DOI: 10.3233/Jad-170927  0.691
2018 De Roeck A, Duchateau L, Van Dongen J, Cacace R, Bjerke M, Van den Bossche T, Cras P, Vandenberghe R, De Deyn PP, Engelborghs S, Van Broeckhoven C, Sleegers K. An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. Acta Neuropathologica. PMID 29589097 DOI: 10.1007/S00401-018-1841-Z  0.324
2018 Goossens J, Bjerke M, Van Mossevelde S, Van den Bossche T, Goeman J, De Vil B, Sieben A, Martin JJ, Cras P, De Deyn PP, Van Broeckhoven C, van der Zee J, Engelborghs S. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. Alzheimer's Research & Therapy. 10: 31. PMID 29559004 DOI: 10.1186/S13195-018-0364-0  0.366
2018 Janssens J, Vermeiren Y, Fransen E, Aerts T, Van Dam D, Engelborghs S, De Deyn PP. Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 172-181. PMID 29552632 DOI: 10.1016/J.Dadm.2018.01.002  0.42
2017 Piersma D, Fuermaier ABM, De Waard D, Davidse RJ, De Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, et al. Assessing Fitness to Drive in Patients With Different Types of Dementia. Alzheimer Disease and Associated Disorders. PMID 29189301 DOI: 10.1097/Wad.0000000000000221  0.348
2017 Geijselaers SLC, Aalten P, Ramakers IHGB, De Deyn PP, Heijboer AC, Koek HL, OldeRikkert MGM, Papma JM, Reesink FE, Smits LL, Stehouwer CDA, Teunissen CE, Verhey FRJ, van der Flier WM, Biessels GJ, et al. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 29154275 DOI: 10.3233/JAD-170522  0.31
2017 Versijpt J, Tant M, Beyer I, Bier JC, Cras P, De Deyn PP, De Wit P, Deryck O, Hanseeuw B, Lambert M, Lemper JC, Mormont E, Petrovic M, Picard G, Salmon E, et al. Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. Acta Neurologica Belgica. PMID 28983881 DOI: 10.1007/S13760-017-0840-5  0.338
2017 Niemantsverdriet E, Ottoy J, Somers C, De Roeck E, Struyfs H, Soetewey F, Verhaeghe J, Van den Bossche T, Van Mossevelde S, Goeman J, De Deyn PP, Mariën P, Versijpt J, Sleegers K, Van Broeckhoven C, et al. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. Journal of Alzheimer's Disease : Jad. PMID 28869470 DOI: 10.3233/Jad-170327  0.314
2017 Goossens J, Bjerke M, Struyfs H, Niemantsverdriet E, Somers C, Van den Bossche T, Van Mossevelde S, De Vil B, Sieben A, Martin JJ, Cras P, Goeman J, De Deyn PP, Van Broeckhoven C, van der Zee J, et al. No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis. Alzheimer's Research & Therapy. 9: 49. PMID 28709448 DOI: 10.1186/S13195-017-0275-5  0.39
2017 Yin Z, Raj D, Saiepour N, Van Dam D, Brouwer N, Holtman IR, Eggen BJL, Möller T, Tamm JA, Abdourahman A, Hol EM, Kamphuis W, Bayer TA, De Deyn PP, Boddeke E. Immune hyperreactivity of Aβ plaque-associated microglia in Alzheimer's disease. Neurobiology of Aging. PMID 28434692 DOI: 10.1016/j.neurobiolaging.2017.03.021  0.33
2017 Dekker AD, Fortea J, Blesa R, De Deyn PP. Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 1-10. PMID 28413821 DOI: 10.1016/j.dadm.2017.02.006  0.396
2016 Janssen L, Dubbelaar ML, Holtman IR, de Boer-Bergsma J, Eggen BJ, Boddeke HW, De Deyn PP, Van Dam D. Aging, microglia and cytoskeletal regulation are key factors in the pathological evolution of the APP23 mouse model for Alzheimer's disease. Biochimica Et Biophysica Acta. PMID 27838490 DOI: 10.1016/j.bbadis.2016.11.014  0.315
2016 Dekens DW, Naudé PJ, Engelborghs S, Vermeiren Y, Van Dam D, Oude Voshaar RC, Eisel UL, De Deyn PP. Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. Journal of Alzheimer's Disease : Jad. PMID 27716662 DOI: 10.3233/Jad-160330  0.338
2016 Goossens J, Laton J, Van Schependom J, Gielen J, Struyfs H, Van Mossevelde S, Van den Bossche T, Goeman J, De Deyn PP, Sieben A, Martin JJ, Van Broeckhoven C, van der Zee J, Engelborghs S, Nagels G. EEG Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease : Jad. PMID 27636837 DOI: 10.1016/J.Jalz.2016.06.656  0.307
2016 Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, De Roeck E, De Vil B, Cras P, Martin JJ, De Deyn PP, Bjerke M, Engelborghs S. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. Journal of Alzheimer's Disease : Jad. 54: 383-95. PMID 27567807 DOI: 10.1016/J.Jalz.2016.06.918  0.42
2016 Vermeiren Y, Janssens J, Aerts T, Martin JJ, Sieben A, Van Dam D, De Deyn PP. Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 27314528 DOI: 10.3233/JAD-160320  0.362
2016 Niemantsverdriet E, Goossens J, Struyfs H, Martin JJ, Goeman J, De Deyn PP, Vanderstichele H, Engelborghs S. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 51: 97-106. PMID 26836187 DOI: 10.3233/Jad-150953  0.404
2016 Hubin E, Vanschoenwinkel B, Broersen K, De Deyn PP, Koedam N, van Nuland NA, Pauwels K. Could ecosystem management provide a new framework for Alzheimer's disease? Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 65-74.e1. PMID 26341147 DOI: 10.1016/j.jalz.2015.07.491  0.307
2015 De Deyn PP. Dementia: Cerebrospinal fluid biomarkers in dementias. Nature Reviews. Neurology. 11: 549-50. PMID 26369513 DOI: 10.1038/nrneurol.2015.175  0.352
2015 Dekker AD, Strydom A, Coppus AM, Nizetic D, Vermeiren Y, Naudé PJ, Van Dam D, Potier MC, Fortea J, De Deyn PP. Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease? Cortex; a Journal Devoted to the Study of the Nervous System and Behavior. 73: 36-61. PMID 26343344 DOI: 10.1016/j.cortex.2015.07.032  0.369
2015 Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin JJ, De Deyn PP, Engelborghs S. Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. Frontiers in Neurology. 6: 138. PMID 26136723 DOI: 10.3389/Fneur.2015.00138  0.37
2015 Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clinical Chemistry. 61: 734-43. PMID 25869575 DOI: 10.1373/Clinchem.2014.236679  0.672
2015 Cuyvers E, van der Zee J, Bettens K, Engelborghs S, Vandenbulcke M, Robberecht C, Dillen L, Merlin C, Geerts N, Graff C, Thonberg H, Chiang HH, Pastor P, Ortega-Cubero S, Pastor MA, ... ... De Deyn PP, et al. Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging. 36: 2005.e15-22. PMID 25796131 DOI: 10.1016/J.Neurobiolaging.2015.02.014  0.351
2015 Braat S, D'Hulst C, Heulens I, De Rubeis S, Mientjes E, Nelson DL, Willemsen R, Bagni C, Van Dam D, De Deyn PP, Kooy RF. The GABAA Receptor is an FMRP Target with Therapeutic Potential in Fragile X Syndrome. Cell Cycle (Georgetown, Tex.). 0. PMID 25790165 DOI: 10.4161/15384101.2014.989114  0.715
2015 Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, Martin JJ, De Deyn PP. The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Research & Therapy. 7: 7. PMID 25717350 DOI: 10.1186/S13195-014-0090-1  0.325
2015 Niemantsverdriet E, Feyen BF, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, Engelborghs S. Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. Journal of Alzheimer's Disease : Jad. 45: 1039-43. PMID 25633672 DOI: 10.3233/Jad-142103  0.69
2015 Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, De Deyn PP, Streffer JR, Mercken M, Engelborghs S. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis. Journal of Alzheimer's Disease : Jad. 45: 813-22. PMID 25633670 DOI: 10.3233/Jad-141986  0.385
2015 Naudé PJ, Dekker AD, Coppus AM, Vermeiren Y, Eisel UL, van Duijn CM, Van Dam D, De Deyn PP. Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome. Journal of Alzheimer's Disease : Jad. 45: 733-43. PMID 25613101 DOI: 10.3233/JAD-142514  0.35
2015 Bier JC, Verschraegen J, Vandenberghe R, Guillaume B, Picard G, Otte G, Mormont E, Gilles C, Segers K, Sieben A, Thiery E, Ventura M, De Deyn P, Deryck O, Versijpt J, et al. Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. Acta Neurologica Belgica. PMID 25576445 DOI: 10.1007/S13760-014-0423-7  0.33
2015 Dorey A, Tholance Y, Vighetto A, Perret-Liaudet A, Lachman I, Krolak-Salmon P, Wagner U, Struyfs H, De Deyn PP, El-Moualij B, Zorzi W, Meyronet D, Streichenberger N, Engelborghs S, Kovacs GG, et al. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. Jama Neurology. 72: 267-75. PMID 25559883 DOI: 10.1001/Jamaneurol.2014.4068  0.373
2015 Van der Mussele S, Mariën P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S. Psychosis associated behavioral and psychological signs and symptoms in mild cognitive impairment and Alzheimer's dementia. Aging & Mental Health. 19: 818-28. PMID 25323000 DOI: 10.1080/13607863.2014.967170  0.334
2015 Dekker AD, Coppus AM, Vermeiren Y, Aerts T, van Duijn CM, Kremer BP, Naudé PJ, Van Dam D, De Deyn PP. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome. Journal of Alzheimer's Disease : Jad. 43: 871-91. PMID 25125467 DOI: 10.3233/JAD-140783  0.367
2015 Van der Mussele S, Le Bastard N, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia. Aging & Mental Health. 19: 247-57. PMID 24962058 DOI: 10.1080/13607863.2014.924900  0.7
2014 Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Mariën P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S. Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study. Journal of Alzheimer's Disease : Jad. 42: 1239-50. PMID 25024328 DOI: 10.3233/Jad-140405  0.302
2014 Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, De Deyn PP. Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiology of Aging. 35: 2691-700. PMID 24997673 DOI: 10.1016/J.Neurobiolaging.2014.05.031  0.332
2014 Struyfs H, Molinuevo JL, Martin JJ, De Deyn PP, Engelborghs S. Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls. Journal of Alzheimer's Disease : Jad. 41: 903-9. PMID 24705548 DOI: 10.3233/Jad-131085  0.398
2014 Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, De Deyn PP. Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 41: 819-33. PMID 24685637 DOI: 10.3233/Jad-140309  0.331
2014 Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ, De Deyn PP, Engelborghs S. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S290-8. PMID 24439167 DOI: 10.1016/J.Jalz.2013.10.004  0.708
2014 Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N, Maes G, Mattheijssens M, Peeters K, Cras P, Vandenberghe R, ... De Deyn PP, et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging. 35: 726.e11-9. PMID 24119542 DOI: 10.1016/J.Neurobiolaging.2013.09.009  0.373
2014 Reesink FE, Stormezand GN, De Deyn PP, Dierckx RAJO. Nuclear imaging in frontotemporal dementia Pet and Spect in Neurology. 339-357. DOI: 10.1007/978-3-642-54307-4_15  0.358
2014 Vermeiren Y, van Dam D, de Deyn PP. Psychiatric disorders in dementia Pet and Spect in Psychiatry. 271-324. DOI: 10.1007/978-3-642-40384-2_11  0.359
2013 Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. Journal of Alzheimer's Disease : Jad. 36: 759-67. PMID 23666174 DOI: 10.3233/Jad-130107  0.706
2013 Van Dam D, Van Dijck A, Janssen L, De Deyn PP. Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunities. Current Alzheimer Research. 10: 449-68. PMID 23627705 DOI: 10.2174/1567205011310050001  0.307
2013 Chapuis J, Hansmannel F, Gistelinck M, Mounier A, Van Cauwenberghe C, Kolen KV, Geller F, Sottejeau Y, Harold D, Dourlen P, Grenier-Boley B, Kamatani Y, Delepine B, Demiautte F, Zelenika D, ... ... De Deyn PP, et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Molecular Psychiatry. 18: 1225-34. PMID 23399914 DOI: 10.1038/Mp.2013.1  0.334
2013 Cacace R, Van Cauwenberghe C, Bettens K, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Bäumer V, Dillen L, Mattheijssens M, Peeters K, Cruts M, Vandenberghe R, De Deyn PP, et al. C9orf72 G4C2 repeat expansions in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging. 34: 1712.e1-7. PMID 23352322 DOI: 10.1016/J.Neurobiolaging.2012.12.019  0.386
2013 De Deyn PP, Drenth AF, Kremer BP, Oude Voshaar RC, Van Dam D. Aripiprazole in the treatment of Alzheimer's disease. Expert Opinion On Pharmacotherapy. 14: 459-74. PMID 23350964 DOI: 10.1517/14656566.2013.764989  0.319
2013 Engelborghs S, Sleegers K, Van der Mussele S, Le Bastard N, Brouwers N, Van Broeckhoven C, De Deyn PP. Brain-specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 35: 67-73. PMID 23334703 DOI: 10.3233/Jad-101305  0.698
2013 Van der Mussele S, Bekelaar K, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S. Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease. International Journal of Geriatric Psychiatry. 28: 947-58. PMID 23255479 DOI: 10.1002/Gps.3909  0.697
2013 Vermeiren Y, Le Bastard N, Van Hemelrijck A, Drinkenburg WH, Engelborghs S, De Deyn PP. Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 488-98. PMID 23159046 DOI: 10.1016/J.Jalz.2012.06.010  0.67
2013 Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 33: 807-22. PMID 23034521 DOI: 10.3233/JAD-2012-110029  0.715
2013 Van der Mussele S, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S. Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. International Journal of Geriatric Psychiatry. 28: 265-75. PMID 22549770 DOI: 10.1002/Gps.3820  0.684
2012 Heulens I, D'Hulst C, Van Dam D, De Deyn PP, Kooy RF. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behavioural Brain Research. 229: 244-9. PMID 22285772 DOI: 10.1016/J.Bbr.2012.01.031  0.718
2012 Bettens K, Brouwers N, Engelborghs S, Lambert JC, Rogaeva E, Vandenberghe R, Le Bastard N, Pasquier F, Vermeulen S, Van Dongen J, Mattheijssens M, Peeters K, Mayeux R, St George-Hyslop P, Amouyel P, ... De Deyn PP, et al. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Molecular Neurodegeneration. 7: 3. PMID 22248099 DOI: 10.1186/1750-1326-7-3  0.647
2011 Wostyn P, Van Dam D, Audenaert K, De Deyn PP. Genes involved in cerebrospinal fluid production as candidate genes for late-onset Alzheimer's disease: A hypothesis Journal of Neurogenetics. 25: 195-200. PMID 22023247 DOI: 10.3109/01677063.2011.620191  0.351
2011 Wostyn P, Van Dam D, Audenaert K, De Deyn PP. Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease. International Journal of Alzheimer's Disease. 2011: 617420. PMID 21660211 DOI: 10.4061/2011/617420  0.357
2011 Wostyn P, Van Dam D, Audenaert K, De Deyn PP. Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease. International Journal of Alzheimer's Disease. 2011: 617420. PMID 21660211 DOI: 10.4061/2011/617420  0.357
2011 Vermeiren Y, Le Bastard N, Clark CM, Engelborghs S, De Deyn PP. Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease. Neurochemical Research. 36: 1858-62. PMID 21597934 DOI: 10.1007/s11064-011-0504-4  0.689
2011 Wostyn P, Audenaert K, De Deyn PP. Choroidal Proteins Involved in Cerebrospinal Fluid Production may be Potential Drug Targets for Alzheimer's Disease Therapy. Perspectives in Medicinal Chemistry. 5: 11-7. PMID 21487536 DOI: 10.4137/PMC.S6509  0.316
2011 Wostyn P, Audenaert K, De Deyn PP. Choroidal Proteins Involved in Cerebrospinal Fluid Production may be Potential Drug Targets for Alzheimer's Disease Therapy. Perspectives in Medicinal Chemistry. 5: 11-7. PMID 21487536 DOI: 10.4137/PMC.S6509  0.316
2010 Aries MJ, Le Bastard N, Debruyne H, Van Buggenhout M, Nagels G, De Deyn PP, Engelborghs S. Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories. International Journal of Geriatric Psychiatry. 25: 1186-95. PMID 20957694 DOI: 10.1002/Gps.2481  0.674
2010 De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Archives of Neurology. 67: 949-56. PMID 20697045 DOI: 10.1001/Archneurol.2010.179  0.354
2010 Brouwers N, Bettens K, Gijselinck I, Engelborghs S, Pickut BA, Van Miegroet H, Montoya AG, Mattheijssens M, Peeters K, De Deyn PP, Cruts M, Sleegers K, Van Broeckhoven C. Contribution of TARDBP to Alzheimer's disease genetic etiology. Journal of Alzheimer's Disease : Jad. 21: 423-30. PMID 20555136 DOI: 10.3233/Jad-2010-100198  0.306
2010 Chen CC, Engelborghs S, Dewaele S, Le Bastard N, Martin JJ, Vanhooren V, Libert C, De Deyn PP. Altered serum glycomics in Alzheimer disease: a potential blood biomarker? Rejuvenation Research. 13: 439-44. PMID 20426627 DOI: 10.1089/Rej.2009.0992  0.718
2010 Le Bastard N, Leurs J, Blomme W, De Deyn PP, Engelborghs S. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. Journal of Alzheimer's Disease : Jad. 21: 291-301. PMID 20421698 DOI: 10.3233/Jad-2010-091501  0.708
2010 Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiology of Aging. 31: 1867-76. PMID 19150153 DOI: 10.1016/J.Neurobiolaging.2008.10.017  0.725
2010 Van Dam D, Coen K, De Deyn PP. Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model Journal of Psychopharmacology. 24: 383-388. PMID 18957478 DOI: 10.1177/0269881108097630  0.336
2009 Wostyn P, Audenaert K, De Deyn PP. More advanced Alzheimer's disease may be associated with a decrease in cerebrospinal fluid pressure. Cerebrospinal Fluid Research. 6: 14. PMID 19917128 DOI: 10.1186/1743-8454-6-14  0.337
2009 Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S. No correlation between time-linked plasma and CSF Abeta levels. Neurochemistry International. 55: 820-5. PMID 19695299 DOI: 10.1016/j.neuint.2009.08.006  0.666
2009 Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochemistry International. 55: 214-8. PMID 19524111 DOI: 10.1016/J.Neuint.2009.02.017  0.717
2009 Wostyn P, Audenaert K, De Deyn PP. Alzheimer's disease and glaucoma: is there a causal relationship? The British Journal of Ophthalmology. 93: 1557-9. PMID 19286688 DOI: 10.1136/bjo.2008.148064  0.326
2009 Debruyne H, Van Buggenhout M, Le Bastard N, Aries M, Audenaert K, De Deyn PP, Engelborghs S. Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? International Journal of Geriatric Psychiatry. 24: 556-62. PMID 19132643 DOI: 10.1002/Gps.2154  0.621
2009 D'Hulst C, Heulens I, Brouwer JR, Willemsen R, De Geest N, Reeve SP, De Deyn PP, Hassan BA, Kooy RF. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Research. 1253: 176-83. PMID 19070606 DOI: 10.1016/J.Brainres.2008.11.075  0.718
2008 Aries MJ, Debruyne H, Engelborghs S, Le Bastard N, Somers N, Gorissen D, Pickut BA, De Deyn PP. Reversal of head drop after discontinuation of olanzapine in a DLB patient. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1760-2. PMID 18661562 DOI: 10.1002/Mds.22182  0.625
2008 Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M, Mariën P, Somers N, Nagels G, Pickut BA, De Deyn PP. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochemistry International. 52: 1052-60. PMID 18093695 DOI: 10.1016/J.Neuint.2007.10.018  0.694
2008 Aalten P, Verhey FR, Boziki M, Brugnolo A, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Holmes C, Hurt C, Marriott A, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dementia and Geriatric Cognitive Disorders. 25: 1-8. PMID 18025783 DOI: 10.1159/000111082  0.34
2008 Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiology of Aging. 29: 1143-59. PMID 17428581 DOI: 10.1016/j.neurobiolaging.2007.02.016  0.386
2007 Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Girtler N, Holmes C, Hurt C, Marriott A, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dementia and Geriatric Cognitive Disorders. 24: 457-63. PMID 17986816 DOI: 10.1159/000110738  0.404
2007 Le Bastard N, Van Buggenhout M, De Leenheir E, Martin JJ, De Deyn PP, Engelborghs S. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 62: 923-4; author reply . PMID 17702886 DOI: 10.1093/Gerona/62.8.923  0.685
2007 Wollmer MA, Sleegers K, Ingelsson M, Zekanowski C, Brouwers N, Maruszak A, Brunner F, Huynh KD, Kilander L, Brundin RM, Hedlund M, Giedraitis V, Glaser A, Engelborghs S, De Deyn PP, et al. Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics. 8: 179-88. PMID 17387528 DOI: 10.1007/S10048-007-0087-Z  0.316
2006 Vloeberghs E, Van Dam D, Coen K, Staufenbiel M, De Deyn PP. Aggressive male APP23 mice modeling behavioral alterations in dementia. Behavioral Neuroscience. 120: 1380-3. PMID 17201483 DOI: 10.1037/0735-7044.120.6.1380  0.303
2006 D'Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, Kooy RF. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Research. 1121: 238-45. PMID 17046729 DOI: 10.1016/J.Brainres.2006.08.115  0.721
2006 Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Mariën P, De Deyn PP. Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochemistry International. 48: 286-95. PMID 16434124 DOI: 10.1016/J.Neuint.2005.11.002  0.363
2006 Engelborghs S, Dermaut B, Mariën P, Symons A, Vloeberghs E, Maertens K, Somers N, Goeman J, Rademakers R, Van den Broeck M, Pickut B, Cruts M, Van Broeckhoven C, De Deyn PP. Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiology of Aging. 27: 285-92. PMID 16399213 DOI: 10.1016/J.Neurobiolaging.2005.02.005  0.401
2006 Brouwers N, Sleegers K, Engelborghs S, Bogaerts V, van Duijn CM, De Deyn PP, Van Broeckhoven C, Dermaut B. The UBQLN1 polymorphism, UBQ-8i, at 9q22 is not associated with Alzheimer's disease with onset before 70 years. Neuroscience Letters. 392: 72-4. PMID 16214290 DOI: 10.1016/J.Neulet.2005.08.064  0.314
2005 Robert PH, Verhey FR, Byrne EJ, Hurt C, De Deyn PP, Nobili F, Riello R, Rodriguez G, Frisoni GB, Tsolaki M, Kyriazopoulou N, Bullock R, Burns A, Vellas B. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. European Psychiatry : the Journal of the Association of European Psychiatrists. 20: 490-6. PMID 16310680 DOI: 10.1016/j.eurpsy.2004.09.031  0.364
2005 De Deyn PP, Engelborghs S, Saerens J, Goeman J, Mariën P, Maertens K, Nagels G, Martin JJ, Pickut BA. The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. International Journal of Geriatric Psychiatry. 20: 70-9. PMID 15578673 DOI: 10.1002/Gps.1249  0.375
2004 Engelborghs S, Vloeberghs E, Maertens K, Mariën P, Somers N, Symons A, Clement F, Ketels V, Saerens J, Goeman J, Pickut BA, Vandevivere J, De Deyn PP. Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia. International Journal of Geriatric Psychiatry. 19: 365-70. PMID 15065230 DOI: 10.1002/Gps.1092  0.303
2004 Van Everbroeck B, Dobbeleir I, De Waele M, De Deyn P, Martin JJ, Cras P. Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. Journal of Neurology. 251: 298-304. PMID 15015009 DOI: 10.1007/s00415-004-0311-9  0.398
Show low-probability matches.